Homology Medicines Inc.

NASDAQ: FIXX · Real-Time Price · USD
0.93
0.00 (0.26%)
At close: Mar 25, 2024, 9:00 PM

Homology Medicines Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 1.16M 3.21M 33.97M
Cost of Revenue
n/a 578K 2.6M 9.54M
Gross Profit
n/a 578K 609K 24.43M
Operating Income
-66.1M -92.1M -133.28M -95.95M
Interest Income
n/a 5.58M 3.23M 185K
Pretax Income
-46.09M -87.08M 1.2M -95.76M
Net Income
-47.73M -112.96M 483K -95.58M
Selling & General & Admin
17.96M 30.68M 38.14M 36.84M
Research & Development
48.14M 62M 98.35M 93.08M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
66.1M 92.68M 136.49M 129.92M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a -578K n/a n/a
Cost & Expenses
n/a 93.26M 136.49M 129.92M
Income Tax Expense
-21K 25.88M 715K -185K
Shares Outstanding (Basic)
9.32M 321.3K 318.89K 307.13K
Shares Outstanding (Diluted)
9.66M 321.3K 318.89K 307.13K
EPS (Basic)
-5.12 -351.57 1.51 -311.2
EPS (Diluted)
-4.94 -351.57 1.51 -311.2
EBITDA
-66.1M -91.52M -133.28M -87.6M
EBIT
n/a -92.1M -259.04M -95.95M
Depreciation & Amortization
n/a 578K -129.96M 8.35M